complement component 3a antagonists (RWJ)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Namecomplement component 3a antagonists (RWJ)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsAsthmaArthritis, RheumatoidShock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRW Johnson Pharmaceutical Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRW Johnson Pharmaceutical Research Institute
Active IndicationsN/A
Inactive IndicationsAsthmaArthritis, RheumatoidShock, Septic

Other Information

ATC CodeN/A
Related LinksN/A